The Cystic Fibrosis team at Manchester Adult Cystic Fibrosis Centre (MACFC) has recruited the first participant in the world to a research study investigating a new anti-fungal drug. The trial is being conducted at Manchester Clinical Research Facility (CRF) at Wythenshawe Hospital.
Cystic fibrosis (CF) is a rare disease: there are around 100,000 sufferers across the world, with approximately 10,400 people affected in the UK.
CF affects many different organs, and causes thick and sticky mucus to build up in the lungs and digestive system. This increased mucus can cause lung infections. Lung infection in CF often involves bugs that are rarely encountered in other conditions and includes fungal infections.
This study is recruiting CF patients who have a persistent lung infection. It aims to test if an inhaled (nebulised) medication (PC945) can help to treat Aspergillus fumigatusfungal lung infections.
This study is being led locally at Manchester University NHS Foundation Trust by Professor Andrew Jones, Consultant Physician in Respiratory Medicine and Head of Department at MACFC, Wythenshawe Hospital; Honorary Clinical Chair at the University of Manchester and a Trustee of the UK charity Cystic Fibrosis Trust.
L-R – Kelsey Armitage Senior Clinical Trials Coordinator for Manchester Clinical Research Facility at Wythenshawe Hospital, Natalie Hill CTAP CF Clinical Trial Coordinator, Professor Andy Jones Principal Investigator and Cassie MacNaughton CF Specialist Clinical and Research Nurse.
We are proud and privileged as a team to be at the forefront of cutting edge research into potential eradication of persistent fungal infection in cystic fibrosis.
The study is being led nationally by Professor Stuart Elborn who is based at Queen’s University, Belfast, in collaboration with Royal Brompton & Harefield NHS Foundation Trust based in London. The project is sponsored and funded by Pulmocide Ltd.